A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Avelumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Carcinoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms JAVELIN CHEMOTHERAPY MEDLEY
- Sponsors Pfizer
- 17 Mar 2023 Status changed from completed to discontinued.
- 20 Jan 2023 This trial has been completed in Italy (End Date: 12 Oct 2022) according to European Clinical Trials Database record.
- 19 Jan 2023 This trial has been completed in Hungary (End Date: 20 Dec 2022) according to European Clinical Trials Database record.